# OnCo record nct07598955 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07598955/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07598955", "NCT07598955" ;
  schema:name "Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma"@en ;
  schema:alternateName "SELECT-NK-THYM"@en ;
  schema:description "A phase 1/2 trial of Cyclophosphamide, Fludarabine and EB-CAR30-NK in thymoma and thymic carcinoma, run by Beijing Biotech, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07598955/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07598955> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2026-03-02" ;
  onco:cancers <https://onco.cc/cancers/thymic-epithelial/>, <https://onco.cc/cancers/thymoma/>, <https://onco.cc/cancers/thymic-carcinoma/> ;
  onco:drugs <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/fludarabine/>, <https://onco.cc/drugs/eb-car30-nk/> .